Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 9

1.

A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.

Rowinsky EK, Beeram M, Hammond LA, Schwartz G, De Bono J, Forouzesh B, Chu Q, Latz JE, Hong S, John W, Nguyen B.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):532-9.

2.

Pemetrexed in advanced colorectal cancer.

Louvet C, de Gramont A.

Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):56-62. Review.

3.

Phase I trials of pemetrexed.

Fossella FV, Gatzemeier U.

Semin Oncol. 2002 Apr;29(2 Suppl 5):8-16. Review.

PMID:
12023787
4.

Phase I. Trial of irinotecan plus carboplatin in two dose schedules.

Jones SF, Burris HA 3rd, Hainsworth JD, Yardley DA, Raefsky EA, Miranda FT, Kuzur ME, Willcutt NT, White MB, Greco FA.

Oncology (Williston Park). 2003 May;17(5 Suppl 5):36-40. Review.

PMID:
12800605
5.

Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.

Bleickardt E, Argiris A, Rich R, Blum K, McKeon A, Tara H, Zelterman D, Burtness B, Davies MJ, Murren JR.

Cancer Biol Ther. 2002 Nov-Dec;1(6):646-51. Review.

PMID:
12642688
6.

The role of pemetrexed in the treatment of colorectal cancer.

Hochster H.

Semin Oncol. 2002 Dec;29(6 Suppl 18):54-6. Review.

PMID:
12571812
7.

The potential role of pemetrexed in gastrointestinal cancer.

Meriggi F, Di Biasi B, Caliolo C, Zaniboni A.

Chemotherapy. 2008;54(1):1-8. Epub 2007 Dec 7. Review.

PMID:
18063861
8.

Phase II studies of pemetrexed in metastatic breast and gynecologic cancers.

Smith I.

Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):63-5. Review.

9.

Pemetrexed in advanced NSCLC: a review of the clinical data.

Zinner RG, Fossella FV, Herbst RS.

Oncology (Williston Park). 2004 Jul;18(8 Suppl 5):54-62. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk